Target- |
Mechanism- |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A randomized double blind placebo controlled multicenter phase III study to evaluate the efficacy and safety of Nuvastatic® 300 mg in reducing chemotherapy induced fatigue in patients with metastatic triple negative breast cancer receiving standard chemotherapy - NIL
A randomized double blind placebo controlled parallel group comparative phase III study to evaluate the efficacy and safety of Nuvastatic® 300mg in reducing cancerinduced fatigue in patients with newly diagnosed chemotherapy naïve nonresectable metastatic colorectal cancer receiving standard chemotherapy - NIL
/ Not yet recruitingPhase 2/3 A randomized, double-blind, placebo-controlled, multicenter, phase II/III study to evaluate the efficacy and safety of Nuvastatic® in reducing chemotherapy-induced fatigue in patients with metastatic colorectal cancer receiving 5-fluorouracil.
100 Clinical Results associated with Natureceuticals Sdn. Bhd.
0 Patents (Medical) associated with Natureceuticals Sdn. Bhd.
100 Deals associated with Natureceuticals Sdn. Bhd.
100 Translational Medicine associated with Natureceuticals Sdn. Bhd.